title: Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome.
abstract: OBJECTIVE
  To evaluate serum levels of YKL-40 in patients with pseudoexfoliation syndrome (PEX) in comparison with those of age- and sex-matched healthy subjects.
  
  
  METHODS
  Forty patients with PEX (PEX group) and 40 age- and sex-matched control subjects (control group) were enrolled in the study. An enzyme immunoassay method using the commercially available test MicroVue YKL-40 was used to measure serum YKL-40 concentration. Systolic and diastolic blood pressures, serum levels of high sensitivity C-reactive protein (hsCRP), total cholesterol, low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), and triglycerides were also examined.
  
  
  RESULTS
  The mean age was 54.4±7.6 (ranging 41-65) years in each group. The mean serum YKL-40 level of the PEX group was significantly higher than that of the control group (P<0.001). In addition, the mean serum HsCRP, total cholesterol, LDL, and triglycerides levels were significantly higher, and mean serum HDL level was significantly lower in the PEX group than in the control group (all P<0.001, excluding both P=0.002 for triglycerides and HDL levels). Further, the mean systolic and diastolic blood pressures were significantly higher in the PEX group than in the control group (P₁=0.001 and P₂=0.01, respectively).
  
  
  CONCLUSIONS
  We have shown a relationship between PEX and elevated serum levels of YKL-40. We imply that a better understanding of the role of YKL-40 in the pathogenesis of endothelial dysfunction and atherosclerosis is necessary to develop new therapies for preventing or treating PEX. Further studies are warranted to clarify the clinical relevance of these findings.
authors: Department of Ophthalmology, Recep Tayyip Erdoğan University Medical School, Rize, Turkey. drkemalturkyilmaz@gmail.com
authors: K
authors: K
authors: Türkyılmaz
authors: V
authors: V
authors: Öner
authors: A
authors: A
authors: Kırbas
authors: M S
authors: MS
authors: Sevim
authors: B
authors: B
authors: Sekeryapan
authors: G
authors: G
authors: Özgür
authors: M
authors: M
authors: Durmus
mesh_terms: D054392:Adipokines / Q000097:blood*; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000502:physiology; D002097:C-Reactive Protein / Q000032:analysis; D016022:Case-Control Studies; D000071451:Chitinase-3-Like Protein 1; D002784:Cholesterol / Q000097:blood; D004727:Endothelium / Q000503:physiopathology*; D017889:Exfoliation Syndrome / Q000097:blood* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood; D037102:Lectins / Q000097:blood*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D054392:Adipokines; D015415:Biomarkers; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D037102:Lectins; D014280:Triglycerides; D002097:C-Reactive Protein; D002784:Cholesterol
references: Ophthalmic Surg. 1989 Oct;20(10):697-701
references: 2616110
references: Genomics. 1997 Jul 15;43(2):221-5
references: 9244440
references: Doc Ophthalmol. 2003 May;106(3):215-23
references: 12737497
references: Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):687-94
references: 10073974
references: Am J Ophthalmol. 1997 Nov;124(5):685-7
references: 9372724
references: Scand J Clin Lab Invest. 2006;66(1):45-54
references: 16464786
references: Scand J Rheumatol. 2003;32(4):205-10
references: 14626626
references: Curr Eye Res. 2008 Feb;33(2):159-62
references: 18293186
references: Graefes Arch Clin Exp Ophthalmol. 2004 Sep;242(9):749-54
references: 15052489
references: Acta Ophthalmol Scand. 2002 Dec;80(6):617-9
references: 12485282
references: Lancet. 2001 Feb 3;357(9253):359-60
references: 11211000
references: Eye (Lond). 2009 Feb;23(2):442-7
references: 17932505
references: Rheumatology (Oxford). 2006 Sep;45(9):1148-53
references: 16527878
references: Graefes Arch Clin Exp Ophthalmol. 2011 Mar;249(3):443-8
references: 20740289
references: Dan Med Bull. 2006 May;53(2):172-209
references: 17087877
references: J Glaucoma. 1994 Summer;3(2):176-7
references: 19920577
references: Am J Ophthalmol. 2006 May;141(5):921-937
references: 16678509
references: J Biol Chem. 1995 Nov 3;270(44):26252-6
references: 7592832
references: Nutrition. 2005 Oct;21(10):994-1002
references: 16157236
references: Eur J Biochem. 1998 Jan 15;251(1-2):504-9
references: 9492324
references: Arch Ophthalmol. 1992 Dec;110(12):1757-62
references: 1463419
references: Inflamm Res. 2006 Jun;55(6):221-7
references: 16955240
references: J Biol Chem. 1993 Dec 5;268(34):25803-10
references: 8245017
references: Prog Retin Eye Res. 2000 May;19(3):345-68
references: 10749381
references: J Glaucoma. 2010 Aug;19(6):373-6
references: 19855290
references: Graefes Arch Clin Exp Ophthalmol. 2005 May;243(5):446-9
references: 15599584
references: Ophthalmic Genet. 1998 Dec;19(4):175-85
references: 9895242
references: Am J Ophthalmol. 2003 Jul;136(1):41-6
references: 12834668
references: Exp Cell Res. 1999 Jul 10;250(1):168-73
references: 10388530
references: Ophthalmology. 1993 Mar;100(3):352-5
references: 8460005
references: Int J Cardiol. 2010 Aug 6;143(1):35-42
references: 19223085
references: BMC Ophthalmol. 2006 Feb 23;6:6
references: 16504073
references: Surv Ophthalmol. 2001 Jan-Feb;45(4):265-315
references: 11166342
references: Clin Chim Acta. 2011 Apr 11;412(9-10):709-12
references: 21272568
references: J Glaucoma. 2005 Dec;14(6):482-4
references: 16276281
references: Circulation. 2003 Feb 11;107(5):690-5
references: 12578870
references: Coron Artery Dis. 2008 Jun;19(4):257-63
references: 18480670
references: J Biol Chem. 1995 Jun 2;270(22):13076-83
references: 7768902
references: Eur Heart J. 2009 May;30(9):1066-72
references: 19270316
references: Scand Cardiovasc J. 2008 Oct;42(5):295-302
references: 18615353